FDA Approves Cambridge Company ’s Groundbreaking Drug For Postpartum Depression

(CNN) — For the first time in history, the US Food and Drug Administration has approved a drug specifically indicated for the treatment of postpartum depression, which experts say offers new hope to women and physicians. On Tuesday, the FDA announced the approval of an intravenous infusion of the drug brexanolone, which will be sold as Zulresso. It has been shown in clinical trials to work within hours to treat the symptoms of postpartum depression, a serious mental illness that impacts 1 in 9 new mothers after childbirth. The first drug to treat postpartum depression was approved by the FDA Tuesday. In the U.S., about one in nine mothers experiences depression after having a baby.@drtaranarula has the details https://t.co/8R9q0XIrkM pic.twitter.com/jpcAvr95AM — CBS Evening News (@CBSEveningNews) March 19, 2019 “Postpartum depression is a serious condition that, when severe, can be life-threatening. Women may experience thoughts about harming themselves or harming their child. Postpartum depression can also interfere with the maternal-infant bond. This approval marks the first time a drug has been specifically approved to treat postpartum depression, providing an important new treatment option,” Dr. Tiffany Farchione, acting director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, said in a press announcement on Tuesday. “Because of concerns about serious risks, including excessive sedation o...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health CNN FDA Postpartum Depression Source Type: news